Click here to Register Free

Radiolabeling of therapeutic antibodies is a sophisticated process involving both selection of isotopes with optimal radiation properties and secure mechanisms of isotope attachment. Such antibodies have enhanced potency in cancer therapy, directing potent radiation to specific areas of disease. Process development and cGMP manufacturing for clinical trials of these entities, however, pose logistical challenges best addressed by a team approach, involving more than one company on the route from "concept to clinic". We describe how we, working together as a multi-company collaboration, overcame challenges and produced a new radiolabeled antibody therapeutic. It combines a PSMA-specific targeting antibody with a high-affinity chelator and a beta-emitting isotope with desirable properties for irradiation of metastatic sites in prostate cancer.